Lloyd Mitchell Segal - 01 Mar 2024 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Steve Forte, Attorney-in-Fact
Issuer symbol: RPTX
Transactions as of: 01 Mar 2024
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2024, 21:04:42 UTC
Previous filing: 01 Feb 2023
Next filing: 27 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPTX	Common Shares	Award	$0	+40,000	+47%	$0.000000	124,677	01 Mar 2024	Direct	F1
holding	RPTX	Common Shares						94,466	01 Mar 2024	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RPTX	Employee Stock Option (right to buy)	Award	$0	+237,000		$0.000000	237,000	01 Mar 2024	Common Shares	237,000	$6.95	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of March 1, 2025, March 1, 2026 and March 1, 2027, subject to Reporting Person continuing to provide service through each such date.
F2	These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
F3	Twenty-five percent (25%) of the shares subject to the option shall vest on March 1, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.